Suppr超能文献

核苷转运体与肿瘤微环境中的免疫抑制性腺苷信号:潜在的治疗机会。

Nucleoside transporters and immunosuppressive adenosine signaling in the tumor microenvironment: Potential therapeutic opportunities.

机构信息

The Ohio State University College of Pharmacy, Division of Pharmaceutics and Pharmacology, Columbus, OH 43210, USA.

The Ohio State University College of Pharmacy, Division of Pharmaceutics and Pharmacology, Columbus, OH 43210, USA; The Abigail Wexner Research Institute, Nationwide Children's Hospital, Columbus, OH 43205, USA.

出版信息

Pharmacol Ther. 2022 Dec;240:108300. doi: 10.1016/j.pharmthera.2022.108300. Epub 2022 Oct 22.

Abstract

Adenosine compartmentalization has a profound impact on immune cell function by regulating adenosine localization and, therefore, extracellular signaling capabilities, which suppresses immune cell function in the tumor microenvironment. Nucleoside transporters, responsible for the translocation and cellular compartmentalization of hydrophilic adenosine, represent an understudied yet crucial component of adenosine disposition in the tumor microenvironment. In this review article, we will summarize what is known regarding nucleoside transporter's function within the purinome in relation to currently devised points of intervention (i.e., ectonucleotidases, adenosine receptors) for cancer immunotherapy, alterations in nucleoside transporter expression reported in cancer, and potential avenues for targeting of nucleoside transporters for the desired modulation of adenosine compartmentalization and action. Further, we put forward that nucleoside transporters are an unexplored therapeutic opportunity, and modulation of nucleoside transport processes could attenuate the pathogenic buildup of immunosuppressive adenosine in solid tumors, particularly those enriched with nucleoside transport proteins.

摘要

腺苷区室化通过调节腺苷定位和因此调节细胞外信号转导能力,对免疫细胞功能产生深远影响,从而抑制肿瘤微环境中的免疫细胞功能。核苷转运体负责亲水性腺苷的转运和细胞区室化,是肿瘤微环境中腺苷处置的一个研究较少但至关重要的组成部分。在这篇综述文章中,我们将总结与当前设计的干预点(即胞外核苷酸酶、腺苷受体)有关的嘌呤核苷中核苷转运体功能的已知情况,癌症中报道的核苷转运体表达的改变,以及针对核苷转运体的靶向的潜在途径,以实现对腺苷区室化和作用的期望调节。此外,我们提出核苷转运体是一个未被探索的治疗机会,调节核苷转运过程可以减轻实体瘤中免疫抑制性腺苷的致病积累,特别是那些富含核苷转运蛋白的肿瘤。

相似文献

1
Nucleoside transporters and immunosuppressive adenosine signaling in the tumor microenvironment: Potential therapeutic opportunities.
Pharmacol Ther. 2022 Dec;240:108300. doi: 10.1016/j.pharmthera.2022.108300. Epub 2022 Oct 22.
2
Nucleoside transporters in the purinome.
Neurochem Int. 2014 Jul;73:229-37. doi: 10.1016/j.neuint.2014.03.014. Epub 2014 Apr 3.
3
Adenosine transporters and receptors: key elements for retinal function and neuroprotection.
Vitam Horm. 2015;98:487-523. doi: 10.1016/bs.vh.2014.12.014. Epub 2015 Feb 27.
7
Targeting Adenosine Receptor Signaling in Cancer Immunotherapy.
Int J Mol Sci. 2018 Dec 2;19(12):3837. doi: 10.3390/ijms19123837.
9
Unlocking the adenosine receptor mechanism of the tumour immune microenvironment.
Front Immunol. 2024 Jun 27;15:1434118. doi: 10.3389/fimmu.2024.1434118. eCollection 2024.
10
[Adenosine and its role in physiology].
Cesk Fysiol. 2015;64(1):35-44.

引用本文的文献

1
Extracellular Adenosine in Gastric Cancer: The Role of GCSCs.
Int J Mol Sci. 2025 Aug 6;26(15):7594. doi: 10.3390/ijms26157594.
2
Cellular Uptake of Hybrid PLGA-Lipid Gadolinium Nanoparticles Functionalized for Magnetic Resonance Imaging of Pancreatic Adenocarcinoma Cells.
ACS Nanosci Au. 2025 Apr 24;5(3):184-195. doi: 10.1021/acsnanoscienceau.5c00010. eCollection 2025 Jun 18.
3
The progress and prospects of targeting the adenosine pathway in cancer immunotherapy.
Biomark Res. 2025 May 19;13(1):75. doi: 10.1186/s40364-025-00784-0.
4
Bile acids inhibit equilibrative adenosine transport to alter adenosine receptor signaling in cholestasis.
J Biol Chem. 2025 Apr 30;301(6):108563. doi: 10.1016/j.jbc.2025.108563.
5
Anticancer effects of salvianolic acid A through multiple signaling pathways (Review).
Mol Med Rep. 2025 Jul;32(1). doi: 10.3892/mmr.2025.13541. Epub 2025 Apr 25.
6
Treatment advances in high-grade gliomas.
Front Oncol. 2024 Apr 10;14:1287725. doi: 10.3389/fonc.2024.1287725. eCollection 2024.
7
Novel Adenosine Receptor Antagonists for Treating Cancer and Immune-Related Disorders.
ACS Med Chem Lett. 2023 Nov 8;14(12):1619-1620. doi: 10.1021/acsmedchemlett.3c00473. eCollection 2023 Dec 14.
9
Chemobrain: An accelerated aging process linking adenosine A receptor signaling in cancer survivors.
Int Rev Neurobiol. 2023;170:267-305. doi: 10.1016/bs.irn.2023.08.003. Epub 2023 Aug 25.

本文引用的文献

2
Adenosine-A2A Receptor Pathway in Cancer Immunotherapy.
Front Immunol. 2022 Mar 21;13:837230. doi: 10.3389/fimmu.2022.837230. eCollection 2022.
5
Role of human nucleoside transporters in pancreatic cancer and chemoresistance.
World J Gastroenterol. 2021 Oct 28;27(40):6844-6860. doi: 10.3748/wjg.v27.i40.6844.
6
Cancer biology and molecular genetics of A adenosine receptor.
Oncogene. 2022 Jan;41(3):301-308. doi: 10.1038/s41388-021-02090-z. Epub 2021 Nov 8.
7
Influence of stereochemistry on the activity of rapadocin, an isoform-specific inhibitor of the nucleoside transporter ENT1.
Chem Sci. 2021 Jul 21;12(34):11484-11489. doi: 10.1039/d1sc02295d. eCollection 2021 Sep 1.
8
OncomiRs miR-106a and miR-17 negatively regulate the nucleoside-derived drug transporter hCNT1.
Cell Mol Life Sci. 2021 Dec;78(23):7505-7518. doi: 10.1007/s00018-021-03959-8. Epub 2021 Oct 13.
9
Inhibition of GATA2 in prostate cancer by a clinically available small molecule.
Endocr Relat Cancer. 2021 Nov 24;29(1):15-31. doi: 10.1530/ERC-21-0085.
10
Role of NKT Cells during Viral Infection and the Development of NKT Cell-Based Nanovaccines.
Vaccines (Basel). 2021 Aug 26;9(9):949. doi: 10.3390/vaccines9090949.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验